FDA approves ACE inhibitor oral solution Qbrelis

SILVER SPRING, Md. — The Food and Drug Administration has approved Silvergate Pharmaceuticals’ Qbrelis (lisinopril) oral solution, the company announced Friday. Qbrelis is the first and only FDA-approved oral solution of the ACE inhibitor lisinopril indicated to treat hypertension in adults and pediatric patients 6 years of age and older, the company said.

 

“We are excited to launch our second product focused on pediatric patients and pediatric hypertension” Silvergate Pharmaceuticals president and CEO Frank Segrave said. “Qbrelis provides a ready-to-use oral solution for these children with the additional assurance of an FDA approved medication. As a company, we continue to focus on pediatric medications that are safe, effective, and readily available.”

 

Qbrelis allows for weight-based dosing in pediatric patients who had previously relied on an adjusted adult dose of the drug.